severe aplastic anemia undergoing allogeneic hematopoietic stem cell transplantation
Conditions
Interventions
The control group was treated with triambutol:Patients were treated with the same drugs as in the HTP group, except that rhTPO and TPO-RA were not used.
Haiqu Popa Formation:Haiqu Popa
Sponsors
Suzhou Hongci Blood Disease Hospital
Eligibility
Sex/Gender
All
Age
12 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 12-65, regardless of gender; 2. Patients with severe aplastic anemia undergoing allogeneic hematopoietic stem cell transplantation. 3. ECOG score 0-3; 4. The patient or his/her guardian must be able to understand and be willing to participate in the study and sign the informed consent form; 5. Total bilirubin = 10 times the upper limit of normal and serum creatinine = 1.5 times the upper limit of normal at the start of the study; 6. negative for serum human immunodeficiency virus (HIV) antigen or antibody. 7. Hepatitis C virus (HCV) antibody negative, or HCV antibody positive but HCV-RNA negative; 8. Hepatitis B virus (HBV) surface antigen and core antibody are both negative. If any of them is positive, the quantity of HBV-DNA in peripheral blood should be less than 1 * 10E2IU/ml.
Exclusion criteria
Exclusion criteria: 1. Abnormal liver and kidney function: creatinine level = 177 umol/L (1.5mg/DL), transaminase and bilirubin levels significantly increased (3 times or more higher than the upper limit of normal). 2. Clinically uncontrolled active infections (including bacterial, viral or fungal infections), but patients under effective drug treatment are not excluded; 3. Serious infectious diseases (uncured tuberculosis, pulmonary aspergillosis, viral infection, active hepatitis B/C; when HBsAg and HBcAg are positive, HBV-DNA positive patients should be excluded, and negative patients can enter this clinical trial; HCV-RNA positive hepatitis C patients are excluded). Patients with chronic hepatitis B and albumin level < 3.5g/dL, or ESLD score = 10. 4. Critically ill or complicated by severe liver, kidney, heart, nerve, lung, infectious or metabolic diseases, the patient may not be able to tolerate the treatment plan or may die within 7-10 days. 5. Pregnant or lactating women. 6. Suffering from mental disorders and unable to cooperate with the requirements of treatment and monitoring. 7. Severe cataract. 8. Hypersensitivity to Hydrotripopa. 9. Malignant tumors of other organs at the same time. 10. Those who are conducting clinical trials of other drugs. 11. The patient is unable to understand or comply with the study protocol. 12. The investigator determines that the patient has other reasons for not being eligible to participate in the study, or that participation in the study would pose a significant risk to the patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelets;HB;neutrophil; | — |
Secondary
| Measure | Time frame |
|---|---|
| Platelet and red blood cell transfusion;Whether there is bleeding, the frequency of bleeding and the severity of bleeding;Whether there was secondary erythrocytopenia and thrombocytopenia during the follow-up period.;Treatment-related side effects; | — |
Countries
China
Contacts
Public ContactLimin Liu
Suzhou Hongci Blood Disease Hospital
Outcome results
None listed